Back | Next |
home / stock / rprx / rprx message board
News, Short Squeeze, Breakout and More Instantly...
Tuesday, Agios Pharmaceuticals Inc (NASDAQ:AGIO) agreed to sell its rights to its 15% royalty on potential U.S. net sales ...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clini...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20,...